InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,230.00
(
-0.15%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,078.72
(
-0.01%
)
Post# of 80490
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

biotech_researcher

Send PM Follow Ignore
Followers 83
Posts 12467
Boards Moderated 0
Alias Born 07/25/2008

biotech_researcher

Re: None

Thursday, 01/03/2013 10:17:09 AM

Thursday, January 03, 2013 10:17:09 AM

Post# of 80490
Ariad Pharmaceuticals Inc. (NASDAQ:ARIA): After it surveyed doctors, Oppenheimer is convinced that physicians are more cautious regarding the side effects of ARIAD’s Iclusig drug for refractory CML as a result of the FDA forcing the company to include a boxed warning for the drug. The firm believes that there is a bit of downside risk for consensus estimates, and it keeps its Perform rating on the stock, despite its continued confidence in the drug’s long-term outlook.
Public Reply Private Reply New Post
Keep Last Read
Replies (3) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (3) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up